APA (7th ed.) Citation

Li, J., Wei, F., Xiang, P., Tang, Z., Ding, L., Chen, L. F., . . . Qu, J. A phase III, randomized, controlled noninferiority trial to study the efficacy and safety of imipenem/cilastatin/relebactam (IMI/REL) vs piperacillin/tazobactam (PIP/TAZ) in patients with hospital-acquired bacterial pneumonia (HABP) or ventilator-associated bacterial pneumonia (VABP). Elsevier.

Chicago Style (17th ed.) Citation

Li, Junjie, et al. A Phase III, Randomized, Controlled Noninferiority Trial to Study the Efficacy and Safety of Imipenem/cilastatin/relebactam (IMI/REL) Vs Piperacillin/tazobactam (PIP/TAZ) in Patients with Hospital-acquired Bacterial Pneumonia (HABP) or Ventilator-associated Bacterial Pneumonia (VABP). Elsevier.

MLA (9th ed.) Citation

Li, Junjie, et al. A Phase III, Randomized, Controlled Noninferiority Trial to Study the Efficacy and Safety of Imipenem/cilastatin/relebactam (IMI/REL) Vs Piperacillin/tazobactam (PIP/TAZ) in Patients with Hospital-acquired Bacterial Pneumonia (HABP) or Ventilator-associated Bacterial Pneumonia (VABP). Elsevier.